SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University
Atlanta, Georgia, United States
Shipra Gandhi, MDRecruiting - Iu Health Joe and Shelly Schwarz Cancer Center
Carmel, Indiana, United States
Recruiting - Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
Recruiting - Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana, United States
Recruiting - Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Sheheryar Kabraji, MDRecruiting - Duke University
Durham, North Carolina, United States
Alexandra Thomas, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 2 Jul 2024
- Primary completion
- 31 Dec 2026
- Completion
- 31 Dec 2026
- Last update posted
- 8 May 2026
- Registered enrollment
- 168
- Registry id
- NCT05846789
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.